News Summary: Charges help cut Merck Q4 profit

Published on NewsOK Modified: February 1, 2013 at 4:46 pm •  Published: February 1, 2013
Advertisement
;

PROFIT DROP: Lower sales due to generic competition and one-time charges cut Merck & Co.'s fourth-quarter profit by 7 percent, to $1.4 billion, or 46 cents per share. Sales were down 5 percent, at $11.74 billion.

UNEXPECTED DELAY: Merck said it's reviewing safety and efficacy data from a crucial late-stage patient test of its experimental osteoporosis drug. It will hold off from applying for approval of the drug, odanacatib, until 2014. It had originally planned file in the first half of this year.

FINANCIAL FORECAST: Merck expects 2013 earnings per share of $3.60 to $3.70, excluding charges, and revenue around $47 billion.


Advertisement


Trending Now



AROUND THE WEB

  1. 1
    Former OU coach Sunny Golloway goes off at Auburn
  2. 2
    Chelsea Clinton Is Pregnant
  3. 3
    Tulsa World: Missouri’s Frank Haith positioned to become TU’s basketball coach
  4. 4
    Oklahoma football: Peyton Manning stops by Sooners film session
  5. 5
    VIDEO: A look at the Air Jordan XX9 in Thunder colors
+ show more